Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms SINE

Most Recent Events

  • 22 Nov 2024 Planned End Date changed from 25 Dec 2024 to 25 Dec 2025.
  • 22 Nov 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
  • 01 May 2023 Results (N=30)assessing efficacy and safety of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, published in the European Journal of Haematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top